Author(s): Koshizuka T, Suzutani T
Abstract Share this page
Abstract Therapy for infectious diseases resulting from alpha-herpesvirus infections has been dramatically improved by the development of acyclovir (ACV). ACV is highly specific against herpes simplex virus type 1(HSV-1), herpes simplex virus type 2 (HSV-2) and varicella-zoster virus (VZV) as ACV is specifically phosphorylated by the thymidine kinases (TKs) of these viruses. These viral TKs are important enzymes for viral replication in vivo; therefore, the growth of TK-deficient mutants is impaired. ACV-resistant viruses are rarely isolated from immunocompetent patients but are frequently obtained from immunocompromised patients. Recently, other anti alpha-herpesvirus drugs, such as valacyclovir and famciclovir, have become available for use in Japan, but the need to develop new antiherpetic compounds with different mechanisms of action remains.
This article was published in Nihon Rinsho
and referenced in Journal of Sports Medicine & Doping Studies